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a b s t r a c t
An electrical storm is a life-threatening syndrome that is characterized by clustering of recurrent episodes of
ventricular tachycardia (VT) or ventricular ﬁbrillation (VF) within a relatively short period of time. Electrical
storms occur in awide variety of conditions, and successful treatment depends on a correct understanding of
the mechanism underlying the recurrent arrhythmias. Management of electrical storms is challenging, but
classifying patients according to the type of recurrent arrhythmia (monomorphic VT or polymorphic VT/VF)
and the presence or absence of structural heart disease would aid differential diagnosis and allow for more
speciﬁc therapies.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
The term “electrical storm” describes a state of electrical
instability of the heart characterized by clustering of recurrent
episodes of ventricular tachycardia (VT) or ventricular ﬁbrillation
(VF) in a short period of time. In recent years, implantable
cardioverter deﬁbrillators (ICDs) have signiﬁcantly improved the
survival of patients with VT/VF. However, electrical storms remain
associated with high mortality and morbidity, and have a negative
impact on long-term outcomes [1]. Although there is no consensus
regarding the deﬁnition of an electrical storm, the generally
accepted deﬁnition in clinical practice and recent literature is the
occurrence of Z2 separate VT/VF episodes or Z3 appropriate ICD
therapies for VT/VF in a 24-h period [2]. In more than half of the
patients with an electrical storm, the intervals between the VT/VF
episodes are o1 h, with the shortest interval of o1 min [3]. A
sustained VT/VF that resumes immediately after (Z1 sinus cycle)
successful deﬁbrillation/cardioversion is regarded as a severe form
of electrical storm. This may masquerade as shock-refractory VT/
VF, since a brief sinus period followed by immediate VT/VF
recurrence can be concealed by post-shock electrocardiographic
(ECG) saturation [4]. Therefore, a severe form of electrical storm
might also be responsible for the events that occur in some
patients with shock-refractory VT/VF, which are commonly seen
during cardiopulmonary resuscitation. It is imperative to improve
the treatment strategy for electrical storms, because the incidence
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of electrical storms is not low (10–28% in patients with an ICD
implanted for secondary prevention and 4% for primary preven-
tion) [1].
This review discusses the practical and efﬁcacious management
of electrical storms. Here, I emphasize that the treatment outcome
greatly depends on the understanding of the pathophysiology of
electrical storms. An approach tailored to the underlying mechan-
ism seems essential for successful management.
2. Principles of management
Patients who present with an electrical storm often have
structural heart disease; however, functional electrical abnormal-
ities also provoke electrical storms in patients with structurally
normal hearts. The underlying conditions that cause electrical
storms are listed in Table 1.
Since an electrical storm is a medical emergency, it is generally
managed in line with a treatment algorithm, typically the
Advanced Cardiovascular Life Support (ACLS) protocol [5], regard-
less of the etiology of the electrical storm. Such a pre-speciﬁed
algorithmic approach is highly effective in critical patient care,
which requires a prompt response to life-threatening conditions.
Nevertheless, I propose that treatment should be as speciﬁc to the
underlying mechanism as possible, because electrical storms of
some etiologies actually require a completely opposite treatment.
Speciﬁcally, sympathetic blockade is effective in controlling elec-
trical storms in patients with the majority of structural heart
diseases [6–8], congenital long QT syndrome (LQTS) [9], and
catecholaminergic polymorphic VT (CPVT) [10], whereas sympa-
thetic stimulation with isoproterenol is useful for inhibiting
electrical storms caused by Brugada syndrome [11], early repolar-
ization syndrome [12], and short QT syndrome (SQTS) [13].
Alternatively, antiarrhythmic drugs commonly used for the treat-
ment of electrical storms [5] can aggravate the situation in LQTS by
further lengthening the QT interval [14]. Therefore, an empirical
approach to treat recurrent VT/VF is potentially harmful in certain
cases, and a mechanism-directed therapy would be preferable.
Although it is difﬁcult to perform a complete diagnostic evaluation
during an electrical storm, standard workups such as transthoracic
echocardiography and 12-lead ECG can help one understand
whether patients have structural heart disease, and/or some
speciﬁc ECG ﬁndings including ischemic ST-T changes, abnormal
QT interval, Brugada-type ECG, and others. Myocardial ischemia,
worsening heart failure, and electrolyte disturbances are a com-
mon trigger of electrical storms [15]. If such an inciting factor is
found, emergent revascularization, correcting the electrolyte
abnormality or treatment for heart failure must be performed.
The type of ventricular arrhythmia (monomorphic VT or poly-
morphic VT/VF) responsible for the electrical storm provides an
important diagnostic clue to its pathophysiology (Fig. 1). In this
review, we address the diagnosis and speciﬁc treatments accord-
ing to the type of ventricular arrhythmia and the presence or
absence of structural heart disease.
3. Monomorphic VT storms in structurally normal hearts
The majority of patients with monomorphic VT storm have
structural heart disease, but monomorphic VT storms can occur in
structurally normal hearts on rare occasions [16,17] (Fig. 2).
Monomorphic VT occurring in structurally normal hearts is
referred to as idiopathic VT. The characteristics of idiopathic VT
depend on the origin of the VT. VT arising from the outﬂow tract is
the most common form of idiopathic VT (OT-VT), which is character-
ized by VT with left bundle branch block (LBBB) and inferior axis QRS
morphology. The typical mechanism of OT-VT involves triggered
activity due to cyclic adenosine monophosphate (AMP)-mediated
delayed afterdepolarizations (DADs) [18]. Beta-adrenergic stimula-
tion increases the intracellular cyclic AMP and intracellular Ca2þ
levels, resulting in spontaneous Ca2þ release from the sarcoplasmic
reticulum (SR), DADs, and triggered activity. Therefore, OT-VT can be
suppressed typically by beta-blockers that lower the stimulated
levels of cyclic AMP (and thus decrease intracellular Ca2þ) or non-
dihydropyridine Ca2þ channel blockers (verapamil or diltiazem) that
directly reduce intracellular Ca2þ by inhibiting the inward L-type
Ca2þ current. As a second-line therapy, class IC or III antiarrhythmic
agents are also effective for suppressing OT-VT [19]. Radiofrequency
catheter ablation (RFCA) is a safe and reliable technique for the
treatment of OT-VT, unless it has an epicardial origin that may
require less safe approaches through the coronary venous system, a
subxyphoid approach for RFCA, or surgical ablation (an epicardial
origin is suggested by delayed initial precordial QRS activation as
quantiﬁed by a maximum deﬂection index Z0.55 [20], Q wave
amplitude in aVL to aVR 41.4, or S wave amplitude in V1 Z1.2 mV
[21]). If available, RFCA can be the ﬁrst choice of treatment for OT-VT
not only when OT-VT is refractory to medical therapy, because RFCA
can be a curative treatment for OT-VT. Activation mapping is useful
when seeking the VT origin during an electrical storm. The earliest
activation at successful ablation sites typically precedes the surface
QRS onset by 20–40 ms, with unipolar electrograms exhibiting a QS
pattern with a rapid initial downstroke [22].
Fascicular VT, also known as idiopathic left VT, is the second
leading cause of idiopathic VT. The mechanism of fascicular VT is
supposed to be macro-reentry involving the Purkinje ﬁber net-
work, which connects to the left fascicle [23,24]. Fascicular VT is
sub-classiﬁed based on the ECG morphology (a right bundle
branch block [RBBB] pattern and superior or inferior QRS axis)
and corresponding fascicle coupled to the reentrant circuit: left
posterior fascicular VT, left anterior fascicular VT, and left
upper septal VT [23]. Left posterior fascicle VT is the most common
manifestation. Fascicular VT has a characteristic ECG with a
relatively narrow QRS width that reﬂects the rapid spread of
Table 1
Causes of electrical storms.
Structural heart diseases
Ischemic heart diseases
Acute or recent myocardial infarction
Prior myocardial infarction
Non-ischemic cardiomyopathy
Dilated cardiomyopathy
Hypertrophic cardiomyopathy
Arrhythmogenic right ventricular dysplasia/cardiomyopathy
Valvular heart diseases
Corrected congenital heart diseases
Myocarditis
Cardiac sarcoidosis
Chagas disease
Metastatic cardiac tumor
Abnormal electrical substrate (structurally normal hearts)
Primary causes
Idiopathic
Brugada syndrome
Early repolarization syndrome
Long QT syndrome
Short QT syndrome
Catecholaminergic polymorphic ventricular tachycardia
Secondary causes
Electrolyte abnormalities
Toxic/drug related
Endocrinologic
Perioperative
Iatrogenic (T wave pacing)
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activation using the specialized conduction system. The prognosis
of fascicular VT is usually excellent, but a fascicular VT case with
tachycardia-induced cardiomyopathy leading to a life-threatening
electrical storm has been described [17]. The distinctive feature of
fascicular VT is its sensitivity to verapamil. The efﬁcacy of class I
antiarrhythmic drugs or beta-blockers is variable (can be harmful
[25]), and intravenous verapamil is the ﬁrst-line therapy for
sustained fascicular VT. As with OT-VT, RFCA is highly effective
as a long-term cure. Early activation of the His bundle potential
usually preceding the local ventricular septal electrogram conﬁrms
Recurrent i d ≥3 i t ICD th i d i 24 h ) h k f t VT/VFVT/VF (≥2 ep so es or appropr a e erap es ur ng ours or s oc -re rac ory 
Electrical or pharmacologic cardioversion/defibrillation
Sedation, respiratory, and circulatory assistance if necessary
Medical r  historyand d ug
12-lead ECG, transthoracic echocardiography
Routine labs (electrolytes thyroid function etc ), , .
Structurally normal heart Structural heart disease
Monomorphic VT Polymorphic VT/VF Monomorphic VT Polymorphic VT/VF
OT-VT Congenital LQTS - Ischemic heart
PM-VT
Annular VT Beta-blockersM i
Beta blockers
Procainamide (unless heart Beta-blockers
A i dFocal Purkinje VT agnes umVerapamil
failure)
Class III AADs
reprogramming
m o arone
Revascularization
Beta-blockers
Ca2+ antagonists
CSD
Late Na+ blockade (LQT3)
ICD
Ablation
CSD
Ablation
CSD
Class IC or III AADs
Ablation Acquired LQTS With QT prolongation
Fascicular VT
Discontinue offending drugs
M i
Discontinue offending drugs
M i
Verapamil
agnes um
Pacing
agnes um
Pacing
Ablation SQTS Heart failure
Class IA or III AADs
I t l
Amiodarone
B t bl ksopro ereno e a- oc ers
Heart failure treatment
Brugada syndrome, ERS
Isoproterenol
Ablation
Quinidine
Cil t l b idilos azo , epr
Ablation (Brugada)
CPVT (Normal baseline ECG)
Beta-blockers
V ilerapam
CSD
IVF (Normal baseline ECG)
Verapamil
Abl tia on
Fig. 1. Management of electrical storms. AAD¼antiarrhythmic drugs; CPVT¼catecholaminergic polymorphic ventricular tachycardia; CSD¼cardiac sympathetic denerva-
tion; ERS¼early repolarization syndrome; ICD¼ implantable cardioverter deﬁbrillator; LQTS¼ long QT syndrome; OT-VT¼outﬂow ventricular tachycardia; PM-VT¼papillary
muscle ventricular tachycardia; SQTS¼short QT syndrome; VF¼ventricular ﬁbrillation; VT¼ventricular tachycardia.
Fig. 2. Monomorphic ventricular tachycardia storm in a patient with a structurally normal heart. Continuous electrocardiographic strips in a patient with recurrent syncopal
episodes are shown.
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the close coupling of the VT circuit with the fascicle. The earliest
pre-systolic fascicular potential with or without a late diastolic
Purkinje potential is an optimal ablation target for fascicular
VT [23].
The other uncommon types of idiopathic VT such as non-
reentrant focal Purkinje VT, papillary muscle VT, and mitral/
tricuspid annular VT may also present as incessant or repetitive
forms of monomorphic VT. Importantly, an incessant nature of the
VTs can secondarily decrease the global (not segmental) left
ventricular (LV) function, despite the normal heart structure
[16,17,26]. The prognosis of such patients is excellent if the VT is
controlled by RFCA or medical therapy with complete recovery of
the LV function.
4. Monomorphic VT storms in structural heart disease
Monomorphic VT storms associated with structural heart dis-
ease are the most common type of electrical storm. Reentry is
responsible for most monomorphic VTs. Conduction and repolar-
ization abnormalities lie within heterogeneous areas of scarred
myocardium caused by ﬁbrosis and collagen deposition of various
etiologies (Table 1). Bundles of surviving myoﬁbrils around the
border of the scar provide an anatomic substrate for conduction
pathways, allowing electrically stable reentry. Focal mechanisms
usually play an important role in initiating reentry, but may also
contribute to maintenance of the VT, especially in patients with
non-ischemic cardiomyopathy [27]. An experimental study has
shown that beta-adrenergic stimulation due to sympathetic acti-
vation, which generally follows hemodyamically-unstable VT,
contributes greatly to focal ventricular ectopy and VT recurrence
through the DAD mechanism [28]. Beta-adrenergic stimulation
enhances intracellular Ca2þ overload secondary to rapid activation
during VT, and Ca2þ/calmodulin-dependent protein kinase
II activation may promote Ca2þ handling abnormality and
DADs [29]. The genesis of a DAD requires high membrane respon-
siveness to changes in intracellular Ca2þ (i.e., high intracellular
Ca2þ-membrane voltage coupling gain) [28], and it is known that
Ca2þ-voltage coupling gain increases in heart failure via down-
regulation of the inward rectiﬁer Kþ current and upregulation of
the Naþ–Ca2þ exchange current [30]. Purkinje cells display a
greater propensity to develop a Ca2þ handling abnormality than
ventricular myocytes [31], and DADs seem to arise predominantly
from Purkinje ﬁbers [28]. Furthermore, the Purkinje ﬁber network
itself can serve as a substrate for the VT reentrant circuit by a
similar mechanism to idiopathic fascicular VT in patients with
prior myocardial infarction [32] and non-ischemic cardiomyopathy
[33], leading to a monomorphic VT storm.
Intravenous administration of class I antiarrhythmic drugs can
be used for the treatment of monomorphic VT storms. Procaina-
mide is reported to be superior to lidocaine for termination of
monomorphic VT [34]. However, electrical storms tend to occur in
patients with structural heart disease and severely reduced LV
function, where class I antiarrhythmic drugs can be harmful. In
such cases, class III antiarrhythmic drugs, such as intravenous
amiodarone [5] and nifekalant [35], are useful unless the patient
has a prolonged QT interval.
In light of the role of DADs in triggering monomorphic VT
storm, sympathetic blockade is a key treatment to control the VT
storm. Beta-blockers that suppress DADs by alleviating intracel-
lular Ca2þ overload rank foremost for this purpose. It should be
noted that not all beta-blockers offer the same level of antiar-
rhythmic effects [36], which might depend on beta-1 selectivity, a
lipophilic nature, or other pleiotropic effects. Recent experimental
studies have shown that carvedilol inhibits DADs by a direct
action on ryanodine receptor type 2 (RyR2) independent of its
beta-blocking effect [37]. Future clinical studies are needed to
determine which beta-blocker has the most favorable effects.
Sedation with short-acting anesthetics such as propofol, benzo-
diazepines, and some general anesthesia agents is also helpful in
suppressing VT storms [38], since physical and emotional stresses
in association with electrical storms contribute to the enhance-
ment of sympathetic activity. Sedation may also help prevent any
post-treatment psychological distress [39]. Hence, all patients who
have electrical storms should be sedated appropriately. If a
pharmacologic sympathetic blockade is not sufﬁcient to control
the VT storm, neural modulation with a left or bilateral stellate
ganglion blockade [8] or thoracic epidural anesthesia [40] may be
a potential treatment of choice for VT storms. Owing to limited
data, neural modulation should be reserved for patients who are
resistant to drugs and RFCA.
Currently, RFCA is indicated if pharmacologic therapies are
unsuccessful [41]. Myocardial substrates for reentrant VT and/or
the origin of focal VT are the ablation target for monomorphic VT
storms. Although ablating multiple and unstable VTs is challen-
ging, modern computerized mapping and catheter navigation
technologies enable them to be treated with a substantial success
rate [42]. When the hemodynamics during the VT are sufﬁciently
stable for VT mapping, an ablation target can be localized using
the conventional criteria of activation and entrainment mapping
[43]. It is important to be aware that some types of monomorphic
VT involve the bundle branch (bundle branch reentry) or Purkinje
ﬁbers (similar to fascicular VT) in the VT circuit, as the ablation
target is very different from that of myocardial VT (i.e., the bundle
branch or Purkinje potentials) [32,33]. When the targeted VTs are
unmappable owing to hemodynamic instability, difﬁculty with
induction, or unstable morphology in response to attempted
entrainment pacing, substrate mapping during sinus rhythm is
useful with the assistance of an electroanatomic mapping system
[44]. Substrate modiﬁcation using several RFCA strategies can
render the unmappable VTs non-inducible and suppress mono-
morphic VT storms [45].
If patients with an ICD receive frequent shocks for mono-
morphic VT, the ICD treatment protocol should be reviewed to
determine if device reprogramming is desirable. Programming an
ICD to deliver antitachycardia pacing for a fast VT can reduce the
need for shocks. In the Pain-Free Rx II trial [46], antitachycardia
pacing effectively treated fast VTs (188–250 bpm). The Primary
Prevention Parameters Evaluation (PREPARE) investigators [47]
evaluated the effect of extending the VT duration needed to trigger
ICD shocks to prevent repeated shocks for non-sustained VT. The
PREPARE study patients were less likely to receive a shock in the
ﬁrst year compared with the control patients (9% vs. 17%), without
any increase in arrhythmic syncope. The Multicenter Automatic
Deﬁbrillator Implantation Trial-Reduce Inappropriate Therapy
(MADIT-RIT) trial [48] showed that programming ICD therapies
for VT to Z200 bpm for Z2.5 s or with a prolonged delay in
therapy (60 s for VT between 170 and 199 bpm and 12 s for VT
between 200 and 249 bpm) was associated with a reduction in all-
cause mortality.
5. Polymorphic VT/VF storms in structurally normal hearts
Polymorphic VT/VF storms are relatively rare in structurally
normal hearts but occur in patients with electrical disorders of
primary (genetic) or secondary causes or an unknown etiology,
termed idiopathic VF (Table 1). In this category, differential diag-
nosis is of particular importance because the treatment strategies
differ greatly among the causes of polymorphic VT/VF storms. The
baseline ECG characteristics have a high diagnostic yield for the
primary causes, while gathering the patient's information (medical
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history, drugs, etc.) and identifying extra-cardiac pathologies are the
keys to a correct diagnosis of secondary causes.
If the QT interval is markedly prolonged, the polymorphic VT is
most likely Torsades de points (TdP, a speciﬁc form of polymorphic
VT in which the QRS complexes seem to twist around the iso-
electric line), which is attributable to congenital or acquired LQTS.
Congenital LQTS is an ion channel disorder with at least 15
different related genes. Mutations in the KCNQ1 (LQT1), KCNH2
(LQT2), and SCN5A (LQT3) genes represent the most common
causes of LQTS and account for an estimated 60–75% of the
genotype-positive LQTS cases [49]. On the other hand, acquired
LQTS is caused by QT-prolonging drugs (e.g., antiarrhythmic
drugs, several antibiotics such as macrolides and ﬂuoroquinolones,
antipsychotics, etc.) and an electrolyte imbalance (hypokalemia,
hypocalcemia, or hypomagnesemia) with or without genetic sus-
ceptibility [50]. In LQTS, triggered activity due to early after-
depolarization (EAD) leads to TdP. Recent studies showed that
not only reactivation of the L-type Ca2þ current (ICa,L) but also
spontaneous SR Ca2þ release also play a role in the genesis of
phase 2 EADs [51]. Furthermore, heterogeneous prolongation of
the action potential duration (APD) sets the stage for reentry and
phase 3 EADs caused by electrotonic reexcitation at the sites with
a steep repolarization gradient [51]. The initial treatment for
polymorphic VT storms in LQTS is the discontinuation of possible
QT-prolonging medications and rapid correction of an electrolyte
imbalance, if present. Beta-blockers are the ﬁrst-line therapy for
congenital LQTS (particularly in LQT1 and LQT2), which is asso-
ciated with defective ion channels needed to adequately adapt to
beta-adrenergic stimulation [49]. Left cardiac sympathetic dener-
vation may be useful for LQTS patients who cannot tolerate or are
resistant to beta-blocker therapy [52]. In contrast to congenital
LQTS, beta-blockers may worsen the situation in acquired LQTS
because bradycardia, which is promoted by beta-blockers, further
prolongs the QT interval and heterogeneous repolarization [51].
Thus, temporary pacing is the treatment of choice for patients
with bradycardia-dependent polymorphic VT in LQTS. Isoproter-
enol can be used in the interim while awaiting pacing treatment,
but it might aggravate the polymorphic VT if it does not increase
the heart rate enough to shorten the QT interval, since phase
2 EADs are enhanced by the isoproterenol-induced increase in
Ca2þ inﬂux. Intravenous verapamil blocks ICa,L and effectively
suppresses polymorphic VT refractory to beta-blockers in conge-
nital LQTS [53]. Magnesium modulates Ca2þ ions and has been
called “nature's physiologic Ca2þ blocker.” Intravenous magne-
sium sulfate can facilitate termination of polymorphic VT
associated with LQTS [54]. Magnesium sulfate has few hemody-
namic effects and seems safer for hemodynamically unstable
patients. If the LQTS genotype is known to be LQT3, which is
attributed to a gain-of-function mutation in the SCN5A gene, drugs
with late Naþ current blocking effects such as mexiletine, ranola-
zine, and propranolol are useful [49].
SQTS is relatively rare, but should be considered if the QT
interval is markedly abbreviated and the ST segment is nearly
absent with peaked and symmetrical T waves. Thus far, mutations
in 5 different genes have been found, but genetic testing remains
investigational because these genes account for only a small
proportion of patients with SQTS. Heterogeneous abbreviation of
the action potential in SQTS increases transmural dispersion of
repolarization and promotes the reentry responsible for poly-
morphic VT [55]. Class IA and III antiarrhythmic drugs, including
quinidine, disopyramide, nifekalant, and amiodarone, are effective
in prolonging the QT interval [55,56]. Bun et al. [13] reported that
isoproterenol rapidly suppressed polymorphic VT/VF storms in a
patient with SQTS. Isoproterenol reduced the transmural voltage
gradients, likely because of an increased heart rate (blunting the
transient outward current [Ito] current) and increase in ICa,L.
Brugada syndrome is characterized by a distinct ECG morphol-
ogy, the absence of structural heart disease, and a high risk of
polymorphic VT/VF and sudden cardiac death. To date, 12 muta-
tions in different genes encoding the proteins of Naþ , Ca2þ , and
Kþ channels have been found [57]. Brugada syndrome can present
as an electrical storm [58]. Hypokalemia, high vagal tone, brady-
cardia, and fever are predisposing factors for an electrical storm.
The Brugada-pattern ECG is divided into 3 types. The type 1 ECG
has prominent coved ST segment elevation with a J-point ampli-
tude of Z2 mm, followed by a negative T wave in Z1 lead among
the right precordial leads (V1 and V2) in the second, third, or
fourth intercostal space [59]. A type 1 ECG is a speciﬁc ﬁnding for
the diagnosis of Brugada syndrome. A transmural voltage gradient
is physiologically present, which is attributable to an Ito-mediated
spike-and-dome morphology or notch in the ventricular epicar-
dium, but not the endocardium. A net outward shift in the
membrane currents during phases 1 and 2 of the right ventricular
epicardial action potential results in depression or loss of the action
potential dome and ST-segment elevation, leading to enhancement
of the transmural voltage gradient, phase 2 reentry, and poly-
morphic VT/VF [57]. Isoproterenol has been proven to normalize
ST segment elevation and suppress electrical storms in Brugada
syndrome, likely because isoproterenol increases the ICa,L and aids
recovery of the action potential dome [11]. Class I antiarrhythmic
agents are Naþ channel blockers that shift the net currents during
the early phase of the action potential outwardly and aggravate the
Brugada-pattern ECG changes, therefore, most are contraindicated
because they heighten the risk of VT/VF. However, quinidine
prevents polymorphic VT/VF by blocking the Ito. Other drugs that
can be useful in Brugada syndrome include denopamine and
cilostazol (increasing ICa,L), as well as bepridil (blocking Ito) [11].
Epicardial right ventricular outﬂow tract RFCA of a fractionated
electrogram may be an option for severely affected patients with
polymorphic VT/VF storms [57].
If the 12-lead ECG shows a J-point elevation of Z1 mm, QRS
slurring or notching in Z2 contiguous inferior and/or lateral leads
in a patent with polymorphic VT/VF storm, early repolarization
syndrome is diagnosed [59]. Underlying genetic abnormalities in
early repolarization syndrome have not yet been demonstrated,
except for a reported case with an ATP-sensitive Kþ channel (IKATP)
gene mutation [60]. Early repolarization syndrome and Brugada
syndrome are considered to share common pathophysiologic
mechanisms despite their differing responses to Naþ channel
blockade [61]. As in Brugada syndrome, isoproterenol acutely
suppresses polymorphic VT/VF storms, and quinidine chronically
prevents electrical storms in early repolarization syndrome [12].
One matter of concern is that the early repolarization ECG pattern
may be merely an innocent bystander, as the incidence of the early
repolarization ECG pattern is high in the general population (5%)
[62]. Therefore, if beta-blockers are used in storm patients with
early repolarization of unknown signiﬁcance, it is prudent to use
an ultra-short-acting beta-blocker such as esmolol and landiolol
[7], in case of subsequent isoproterenol infusion.
If a structurally normal patient with polymorphic VT/VF storm
has a completely normal baseline ECG, the possible diagnosis
includes CPVT and idiopathic VF. CPVT is an inherited disorder of
intracellular Ca2þ handling, which can cause polymorphic VT/VF
storms [10]. Abnormal SR Ca2þ release from defective ryanodine
receptors produces DADs, triggering activity in the Purkinje
system, which is the proposed mechanism of polymorphic VT in
CPVT patients. Mutations in the gene encoding RyR2 lead to Ca2þ
leak from the SR in an autosomal dominant form (CPVT1), while
mutations in the gene encoding cardiac calsequestrin (CASQ2), an
SR-buffering protein, lead to the less common autosomal-recessive
form (CPVT2). CPVT1 and CPVT2 account for approximately 60% of
CPVT patients. A history of stress or exertion-induced syncope in a
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young patient is suggestive of CPVT, which is usually tachycardia
dependent. The hallmark of CPVT is bidirectional VT that exhibits
alternating LBBB and RBBB QRS patterns. Beta-blockers are the
mainstay treatment of CPVT, since beta-adrenergic stimulation
increases intracellular Ca2þ , which triggers DADs and polymorphic
VT. An experimental study suggests that carvedilol is the most
effective beta-blocker because it can directly block RyR2 with a
CPVT mutation [37]. Verapamil has an additional effect on CPVT in
cases of electrical storms that are resistant to beta-blockers [10]. A
recent study has shown that ﬂecainide suppresses DADs and CPVT
by inhibiting spontaneous SR Ca2þ release as well as the Naþ
channel [63]; however, its usefulness in electrical storms remains
to be conﬁrmed. If pharmacologic treatment fails to control
the CPVT, left cardiac sympathetic denervation should be consid-
ered [52]. One recent case report has shown that RFCA targeting
premature ventricular VF-triggering contractions was successful
for controlling recurrent CPVTs refractory to beta-blocker therapy
[64].
Idiopathic VF is a clinical entity in which no cardiac anatomic or
functional abnormality can be identiﬁed despite extensive clinical
evaluation for the cause of VF. Therefore, the pathophysiology of
idiopathic VF must include multifactorial disorders of unknown
origin. However, the similar clinical presentation of this entity
indicates that these disorders share some common mechanisms.
Leenhardt et al. [65] ﬁrst described a group of patients consistent
with the clinical picture of idiopathic VF, but they termed it “short-
coupled variant of TdP.” The interesting characteristic observed in
these patients is the unusually short coupling interval of the
precipitating VF (245728 ms). Verapamil was the only effective
drug, supporting the theory that the verapamil-sensitive ventri-
cular myocardium might be involved in permitting triggered
activity and VF. Antiarrhythmic drugs and beta-blockers are
ineffective; in fact, class I antiarrhythmic drugs can be harmful
[66]. It is notable that RFCA of triggered premature ventricular
contractions that emanate from either Purkinje ﬁbers or the
ventricular myocardium, particularly in the right ventricular out-
ﬂow tract, can be successful in suppressing and preventing
electrical storms due to idiopathic VF [66,67]. These observations
also indicate the important role of the Purkinje system in the
genesis of idiopathic VF.
6. Polymorphic VT/VF storms in structural heart disease
In the absence of a prolonged QT interval, the most common
cause of polymorphic VT is myocardial ischemia. Indeed, the
speciﬁc arrhythmia that arises from acute myocardial ischemia is
almost always polymorphic VT/VF. Hence, polymorphic VT/VF
storms in patients with coronary disease are strongly suggestive
of acute myocardial ischemia. Myocardial ischemia leads to repe-
titive inductions of VT through various mechanisms, including
abnormal automaticity with altered membrane potential, trig-
gered activity, and phase 2 reentry. Revascularization procedures
may be urgently needed for polymorphic VT/VF storms associated
with myocardial ischemia. Sympathetic blockade with beta-
blockers or left cardiac sympathetic denervation has been shown
to result in a better outcome than class I antiarrhythmic drugs in
patients with polymorphic VT/VF storms associated with recent
myocardial infarction [6]. Nevertheless, antiarrhythmic drugs
remain a useful adjunctive therapy for controlling polymorphic
VT/VF storms in the presence of ischemia. In ischemic conditions,
lidocaine is believed to be effective by its preferential binding to
fast Naþ channels in ischemic myocytes, but intravenous amio-
darone appears to be more effective than lidocaine and other
antiarrhythmic drugs [68]. In some patients, polymorphic VT/VF
still occurs despite revascularization and medical therapy. Purkinje
ﬁbers are relatively resistant to ischemia, as they are supplied by
cavity blood and have higher glycogen levels and fewer myoﬁbrils.
Following myocardial infarction, surviving Purkinje ﬁbers in
ischemic lesions have increased SR Ca2þ leak and triggered
activity [69]. RFCA aimed at the Purkinje potentials preceding
the QRS onset of ventricular premature contractions that initiate
polymorphic VT/VF can terminate and prevent electrical storms in
patients with acute myocardial infarction [70] and ischemic
cardiomyopathy [71]. During the acute phase of myocardial
infarction, bradycardia-dependent polymorphic VT/VF can occur
with marked QT prolongation [72]. In these cases, pharmacologic
therapies and pacing are useful in the same manner as those used
for acquired LQTS.
Polymorphic VT/VF storms can occur in patients with severe
heart failure, independent of their underlying causes. Recent
experimental studies using a pacing-induced heart failure model
showed that heart failure facilitates acute shortening of the APD
immediately after VF termination [73]. Persistent elevation of
intracellular Ca2þ due to Ca2þ overload following VF activates
inward Ca2þ-sensitive currents during the late phase 3 of the
action potential, which induces triggered activity and spontaneous
VF (i.e., late phase 3 EAD). This arrhythmogenic post-shock APD
shortening after VF deﬁbrillation occurs in heart failure via
upregulation of the apamin-sensitive small-conductance Kþ cur-
rent (IKAS) in failing hearts [74]. In this heart failure model,
blocking IKAS prevents recurrent VF, resulting in the termination
of VF storms. In fact, IKAS upregulation also occurs in human hearts
with severe heart failure [75]. Notably, amiodarone blocks IKAS
[76]. In addition, sympathetic stimulation accelerates post-shock
APD shortening, late phase 3 EADs, and VF recurrence by non-
ischemic activation of IKATP [4]. Myocardial ischemia during VF
further enhances IKATP activation. It has been reported that
amiodarone also inhibits sarcolemmal IKATP [77]. Taken together,
the combined use of intravenous amiodarone and beta-blockers is
a reasonable treatment for polymorphic VT/VF storms in patients
with heart failure.
Amiodarone has been shown to increase the short-term survi-
val of patients with shock-refractory VT/VF when compared with
lidocaine [78]. This beneﬁcial effect of amiodarone may be
partially attributable to the prevention of immediate VT/VF recur-
rence (i.e., severe form of electrical storms) mimicking shock-
refractory VT/VF.
RFCA is also useful in treating polymorphic VT/VF storms
resistant to medical therapies in patients with non-ischemic
cardiomyopathy. Purkinje-like potentials recorded along the scar
border zone can be ablation targets [79].
7. Conclusions
Electrical storms are a life-threatening syndrome and the
appropriateness of acute management determines the patient's
survival. Despite the difﬁculties associated with a comprehensive
evaluation of this critical condition, a diagnostic approach based
on the type of ventricular arrhythmia (monomorphic or poly-
morphic) and the presence or absence of structural heart disease
facilitates the mechanism-directed therapy of electrical storms.
Recent advances in non-pharmacologic treatment, particularly
RFCA, have greatly improved the clinical outcomes. Nonetheless,
optimal pharmacologic treatment remains essential for successful
management of electrical storms.
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